SNYSanofiRunning, no new patients
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 943 (final count)
- Started
- Dec 27, 2023
- Main results expected
- Mar 24, 2028
- Fully finished
- Mar 24, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months in the double-blind treatment period
Measured over: Up to 36 months
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-09 15:36 UTC · paperwork · other
old: null
new: null
details: {"sections":["outcomesModule","statusModule"]}
Trial ID NCT06141486 · record last updated 2026-11-09 · checked 2026-11-09 15:47 UTC